AccurayARAY
About: Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Employees: 987
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
913% more call options, than puts
Call options by funds: $162K | Put options by funds: $16K
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
9% more capital invested
Capital invested by funds: $99.6M [Q3] → $109M (+$9.35M) [Q4]
4% more funds holding
Funds holding: 126 [Q3] → 131 (+5) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.42% less ownership
Funds ownership: 55.17% [Q3] → 54.75% (-0.42%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ARAY.
Financial journalist opinion
Based on 5 articles about ARAY published over the past 30 days
